138 studies found for:    niaid hiv/aids | Open Studies
Show Display Options
Rank Status Study
21 Recruiting Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
Condition: HIV Infections
Interventions: Drug: atazanavir/cobicistat;   Drug: darunavir/ritonavir;   Drug: darunavir/cobicistat;   Drug: etravirine;   Drug: elvitegravir/cobicistat;   Drug: dolutegravir;   Drug: tenofovir alafenamide fumarate (TAF);   Drug: TAF/cobicistat;   Drug: TAF/ritonavir;   Drug: efavirenz;   Drug: lopinavir/ritonavir;   Drug: nevirapine;   Drug: rifampicin;   Drug: ethambutol;   Drug: isoniazid;   Drug: pyrazinamide;   Drug: kanamycin;   Drug: amikacin;   Drug: capreomycin;   Drug: moxifloxacin;   Drug: levofloxacin;   Drug: ofloxacin;   Drug: ethionamide/prothionamide;   Drug: terizidone/cycloserine;   Drug: para-aminosalicylic acid (PAS);   Drug: high dose isoniazid (INH);   Drug: bedaquiline;   Drug: clofazamine;   Drug: delamanid;   Drug: linezolid;   Drug: pretomanid;   Drug: atazanavir/ritonavir/tenofovir;   Drug: ethinyl estradiol oral contraceptive;   Drug: etonogestrel implant
22 Not yet recruiting Vedolizumab (Anti- 4 <=7) in Subjects With HIV Infection Undergoing Analytical Treatment Interruption
Condition: HIV
Intervention: Biological: Entyvio (Vedolizumab)
23 Recruiting Clinical Outcomes in Persons With HIV Acquired Early in Life
Conditions: HIV;   Childhood;   Natural History;   Cardiac;   ART
Intervention:
24 Recruiting Safety and Virologic Effect of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously to HIV-Infected Adults
Condition: HIV-1
Intervention: Biological: VRC-HIVMAB080-00-AB (VRC01LS)
25 Recruiting Viral Load in Blood and Lymph Tissues of HIV-Infected Individuals
Condition: HIV Infection
Intervention:
26 Recruiting IMPAACT P1115: Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission
Condition: HIV Infection
Intervention: Drug: Intensive ART regimen
27 Recruiting Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to Healthy Adults
Conditions: Prevention of HIV Infection;   HIV Antibodies;   Monoclonal Antibody, Human;   Neutralizing Antibody
Intervention: Biological: VRC-HIVMAB080-00-AB
28 Recruiting Blood Markers of Inflammation, Blood Clotting and Blood Vessel Function in HIV-infected Adults
Condition: HIV
Intervention:
29 Recruiting Quantitative Measurement and Correlates of the Latent HIV Reservoir in Virally Suppressed Ugandans
Condition: HIV
Intervention:
30 Recruiting Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Primary and Chronic HIV-Infected Patients
Condition: HIV
Intervention:
31 Recruiting Studies of Blood and Reproductive Fluids in HIV-Infected and Non-HIV-Infected Persons
Condition: HIV Infection
Intervention:
32 Recruiting Study of Safety and Immunogenicity of HIV Vaccines in Healthy Volunteers
Conditions: Healthy Volunteer;   HIV Vaccine
Interventions: Biological: Ad4-mgag;   Biological: Ad4-EnvC150
33 Recruiting Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Condition: HIV-1 Infection
Interventions: Drug: Visibiome;   Drug: Placebo
34 Recruiting Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection
Conditions: HIV-1 Infection;   Hepatitis
Interventions: Drug: Ribavirin;   Drug: Sofosbuvir;   Drug: Ledipasvir/Sofosbuvir
35 Not yet recruiting Evaluating the Safety and Immune Response to Two HIV Vaccine Regimens in Healthy, HIV-Uninfected Adults in the United States and South Africa
Condition: HIV Infections
Interventions: Biological: DNA-HIV-PT123 vaccine;   Biological: NYVAC-HIV-PT1 vaccine;   Biological: NYVAC-HIV-PT4 vaccine;   Biological: AIDSVAX B/E vaccine;   Biological: Placebo for DNA/NYVAC/AIDSVAX
36 Recruiting 12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF
Conditions: HIV-1 Infection;   Hepatitis C
Interventions: Drug: Ledipasvir/sofosbuvir;   Drug: Ribavirin
37 Recruiting Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 28 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
Condition: HIV Infections
Interventions: Drug: Lamivudine/zidovudine;   Drug: Efavirenz;   Drug: Raltegravir
38 Recruiting Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection in Women
Condition: HIV Infections
Interventions: Biological: VRC01;   Biological: Placebo for VRC01
39 Recruiting Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men
Condition: HIV Infections
Interventions: Biological: VRC01;   Biological: Placebo for VRC01
40 Unknown  Safety of an Oral HIV Vaccine in HIV Uninfected Volunteers
Condition: HIV Infections
Intervention: Biological: SCBaL/M9

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years